Advances in Treatments in Muscular Dystrophies and Motor Neuron Disorders

Neurol Clin. 2021 Feb;39(1):87-112. doi: 10.1016/j.ncl.2020.09.005.

Abstract

Increased understanding of disease pathophysiology and advances in gene therapies and drug technologies are revolutionizing treatment of muscular dystrophies and motor neuron disorders (MNDs). New drugs have been approved for Duchenne muscular dystrophy, spinal muscular atrophy, and amyotrophic lateral sclerosis. For other diseases, new targets have been identified, and new therapies are in clinical trials. The impact of such therapies will be fully understood only in the next decades. Cost burden and accessibility are major challenges in the wide application of new drugs. This article reviews advances in gene therapies, newly approved drugs, and therapeutic promises in muscular dystrophies and MNDs.

Keywords: Gene therapy; Motor neuron disorders; Muscular dystrophies; Neuromuscular diseases; Neurotherapeutics.

Publication types

  • Review

MeSH terms

  • Genetic Therapy / methods
  • Humans
  • Motor Neuron Disease / therapy*
  • Muscular Dystrophies / therapy*
  • Neuroprotective Agents / therapeutic use

Substances

  • Neuroprotective Agents